TrakCel, Ori Biotech ink supply chain deal for cell and gene therapy
TrakCel was created in 2012 in order to manage the international autologous and allogeneic cell, gene and immunotherapy supply chain.
Read More
Tag: Ori Biotech
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
